Halozyme Therapeutics HALO Raw materials
Raw materials at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InventoryRawMaterialsNetOfReserves.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's raw materials.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Halozyme Therapeutics's raw materials?
- Halozyme Therapeutics (HALO) reported raw materials of $21.9M in Q1 2026.
- How has Halozyme Therapeutics's raw materials changed year-over-year?
- Halozyme Therapeutics's raw materials increased by 18.9% year-over-year, from $18.42M to $21.9M.
- What is the long-term trend for Halozyme Therapeutics's raw materials?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's raw materials has grown at a 30.3% compound annual growth rate (CAGR), from $5.81M to $21.87M.
- What does raw materials mean?
- Unprocessed materials and components purchased for use in manufacturing, valued at cost.